Warning: The NCBI web site requires JavaScript to function. more...
Possible pathogenic pathways in the adverse clinical events seen following ivermectin administration to onchocerciasis patients.
Mackenzie CD, Geary TG, Gerlach JA.
Filaria J. 2003 Oct 24;2 Suppl 1:S5.
Related citations
Report of a Scientific Working Group on Serious Adverse Events following Mectizan(R) treatment of onchocerciasis in Loa loa endemic areas.
Scientific Working Group on Serious Adverse Events in Loa Loa endemic areas.
Filaria J. 2003 Oct 24;2 Suppl 1:S2.
Three probable cases of Loa loa encephalopathy following ivermectin treatment for onchocerciasis.
Boussinesq M, Gardon J, Gardon-Wendel N, Kamgno J, Ngoumou P, Chippaux JP.
Am J Trop Med Hyg. 1998 Apr;58(4):461-9.
Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported cases.
Twum-Danso NA.
Filaria J. 2003 Oct 24;2 Suppl 1:S3.
Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future.
Filaria J. 2003 Oct 24;2 Suppl 1:S7.
Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon.
Boussinesq M, Gardon J, Gardon-Wendel N, Chippaux JP.
Filaria J. 2003 Oct 24;2 Suppl 1:S4.
Ivermectin: does P-glycoprotein play a role in neurotoxicity?
Edwards G.
Filaria J. 2003 Oct 24;2 Suppl 1:S8.
Programmatic and Communication Issues in Relation to Serious Adverse Events Following Ivermectin Treatment in areas Co-endemic for Onchocerciasis and Loiasis.
Haselow NJ, Akame J, Evini C, Akongo S.
Filaria J. 2003 Oct 24;2 Suppl 1:S10.
Clinical picture and outcome of Serious Adverse Events in the treatment of Onchocerciasis.
Awadzi K.
Filaria J. 2003 Oct 24;2 Suppl 1:S6.
Prevalences of Loa loa microfilaraemia throughout the area endemic for the infection.
Boussinesq M, Gardon J.
Ann Trop Med Parasitol. 1997 Sep;91(6):573-89. Review.
Loa loa microfilarial periodicity in ivermectin-treated patients: comparison between those developing and those free of serious adverse events.
Kamgno J, Pion SD, Mackenzie CD, Thylefors B, Boussinesq M.
Am J Trop Med Hyg. 2009 Dec;81(6):1056-61.
[Analysis of the prevention of post-ivermectin Loa loa encephalopathy by administration of initial low dose].
Kamgno J, Gardon J, Boussinesq M.
Med Trop (Mars). 2000;60(3):275-7. French.
[Ivermectin].
Boussinesq M.
Med Trop (Mars). 2005;65(1):69-79. Review. French.
Variation in incidence of serious adverse events after onchocerciasis treatment with ivermectin in areas of Cameroon co-endemic for loiasis.
Twum-Danso NA, Meredith SE.
Trop Med Int Health. 2003 Sep;8(9):820-31.
Control of onchocerciasis.
Boatin BA, Richards FO Jr.
Adv Parasitol. 2006;61:349-94. Review.
Mass treatment of onchocerciasis with ivermectin: should people with epilepsy and/or growth-retardation syndromes be excluded?
Ann Trop Med Parasitol. 2004 Mar;98(2):99-114. Review.
Adverse reactions from community directed treatment with ivermectin (CDTI) for onchocerciasis and loiasis in Ondo State, Nigeria.
Otubanjo OA, Adeoye GO, Ibidapo CA, Akinsanya B, Okeke P, Atalabi T, Adejai ET, Braide E.
Rev Biol Trop. 2008 Dec;56(4):1635-43.
Combined Utilisation of Rapid Assessment Procedures for Loiasis (RAPLOA) and Onchocerciasis (REA) in Rain forest Villages of Cameroon.
Wanji S, Tendongfor N, Esum M, Yundze SS, Taylor MJ, Enyong P.
Filaria J. 2005 Apr 7;4(1):2.
Adverse reactions to the ivermectin treatment of onchocerciasis patients: does infection with the human immunodeficiency virus play a role?
Kipp W, Bamhuhiiga J, Rubaale T, Kabagambe G.
Ann Trop Med Parasitol. 2005 Jun;99(4):395-402.
Develoux M.
Ann Dermatol Venereol. 2004 Jun-Jul;131(6-7 Pt 1):561-70. Review. French.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on